2seventy bio Management
Management criteria checks 1/4
2seventy bio's CEO is Nick Leschly, appointed in May 2021, has a tenure of 2.25 years. total yearly compensation is $6.08M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 1.11% of the company’s shares, worth MX$65.53M. The average tenure of the management team and the board of directors is 1.8 years and 1.8 years respectively.
Key information
Nick Leschly
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 12.8% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$215m |
| Dec 31 2022 | US$6m | US$780k | -US$254m |
| Sep 30 2022 | n/a | n/a | -US$292m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$291m |
| Dec 31 2021 | US$6m | US$751k | -US$292m |
| Sep 30 2021 | n/a | n/a | -US$308m |
| Jun 30 2021 | n/a | n/a | -US$320m |
| Mar 31 2021 | n/a | n/a | -US$222m |
| Dec 31 2020 | US$6m | US$725k | -US$120m |
Compensation vs Market: Nick's total compensation ($USD6.08M) is above average for companies of similar size in the MX market ($USD611.44K).
Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.
CEO
Nick Leschly (50 yo)
2.3yrs
Tenure
US$6,078,514
Compensation
Mr. Nick Leschly has been a Director of bluebird bio, Inc. since March 2010 and served as its President since September 2010 and as its Chief Executive Officer since September 2010 until 2021. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | US$6.08m | 1.11% MX$ 65.5m | |
| Chief Scientific Officer | 1.8yrs | US$2.53m | 0.065% MX$ 3.9m | |
| Chief Financial Officer | 1.8yrs | US$2.44m | 0% MX$ 0 | |
| Chief Technology & Manufacturing Officer | no data | no data | no data | |
| Senior VP | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Senior Vice President of Corporate Affairs | no data | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Senior Vice President of Development Operations & Portfolio Strategy | less than a year | no data | no data | |
| VP & Head of Genome Editing | no data | no data | no data |
1.8yrs
Average Tenure
51yo
Average Age
Experienced Management: TSVT *'s management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$6.08m | 1.11% MX$ 65.5m | |
| Independent Chairman of the Board | 1.8yrs | US$327.57k | 0.025% MX$ 1.5m | |
| Independent Director | 1.8yrs | US$242.42k | 0.010% MX$ 610.2k | |
| Independent Director | 1.8yrs | US$330.51k | 0.021% MX$ 1.3m | |
| Independent Director | 1.8yrs | US$253.54k | 0.010% MX$ 610.2k | |
| Independent Director | less than a year | no data | no data |
1.8yrs
Average Tenure
57.5yo
Average Age
Experienced Board: TSVT *'s board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/02 03:05 |
| End of Day Share Price | 2023/05/05 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
2seventy bio, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |